Core Viewpoint - The treatment of asthma has evolved from mere symptom control to achieving clinical cure, supported by advancements in modern medicine and the introduction of biological agents [2][3] Group 1: Asthma Treatment Insights - Asthma has the highest prevalence among chronic respiratory diseases globally, while chronic obstructive pulmonary disease (COPD) ranks first in China, with asthma in second place [2] - The clinical cure goals for asthma include four "zeros": no obvious symptoms, no asthma attacks, normal lung function, and no need for oral steroids [2] - Various biological agents such as omalizumab, mepolizumab, benralizumab, and dupilumab have shown promising clinical cure rates, providing more options for patients [2] Group 2: Challenges and Future Directions - The usage rate of biological agents in China is currently low, presenting challenges for broader adoption [2] - Long-term use of biological agents can effectively reduce acute attacks, emergency visits, and hospitalizations, making them cost-effective in overall healthcare expenditure [2] - Ongoing research is focused on developing targeted drugs for different cytokines and pathways, with new biological agents expected to enter clinical use [3] - Achieving the goal of clinical cure for asthma requires collaborative efforts from healthcare providers, patients, government, and society [3]